New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer…

By P. Therasse, S. Arbuck, E. Eisenhauer, J. Wanders, R. Kaplan, L. Rubinstein, J. Verweij, M. V. Van Glabbeke, A. V. van Oosterom, M. Christian and 1 more. Journal of the National Cancer Institute, 2000

8,022 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/50473bc1f2fe6844b74de9e350348301b39aae31

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Reck
2. M. Hellmann
3. S. Topalian
4. E. Cutsem
5. L. Paz-Ares
6. J. Baselga
7. A. Shaw
8. L. Sequist

Citations in the corpus

• Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer (2011, methodology): “%) were stable or progressed under treatment according to RECIST (25).”
• Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. (2012, methodology): “0.(22) Pharmacokinetic Assessments Plasma levels of BKM120 were determined from samples (collected predose and 0.”
• Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2015, unknown): “One can estimate the growth rate of MTC from sequential imaging studies using response evaluation criteria in solid tumors (RECIST) that document incremental increases in tumor size over time (292).”
• Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages (2010, methodology): “evaluation criteria (RECIST criteria [29], clearly defined”
• Image-guided tumor ablation: standardization of terminology and reporting criteria. (2005, unknown): “Although standard imaging criteria for response assessments have been defined for evaluation of other cancer therapies, these criteria focus almost exclusively on tumor size (84).”
• Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma (2010, methodology): “As acknowledged in the original RECIST publication, assessments based solely on changes in tumor size can be misleading when applied to other anticancer drugs, such as molecular-targeted therapies, or other therapeutic interventions.(2) In the case of hepatocellular carcinoma (HCC), recent studies h”
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors (2009, methodology): “RECIST The RESIST criteria were published in 2000 and resulted from the recognition of some limitations of the WHO criteria (8).”
• Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008, background): “Solid Tumors (Response Evaluation Criteria in Solid Tumors [RECIST]).(2) This international initia-”